August 2017 | Official opening of the "Centre for Predictive Drug Discovery" laboratories in Glasgow, Scotland |
May 2017 | Alliance is formed with Fox Chase Medical Center (Philadelphia, U.S.A.) to accelerate biomarker and genetic discovery |
November 2016 | Agreement is signed with Steminent Biopharmaceuticals (Taiwan) for Stemchymal cell therapy technology; REPROCELL Medical business unit is created |
November 2016 | REPROCELL Europe founded with full-trading offices located at the Biopta site in Glasgow, Scotland (U.K.); Dr. David Bunton named CEO. |
August 2016 | REPROCELL USA founded with full-trading offices located at the BioServe site in Beltsville, MD (U.S.A.); Dr. Rama Modali named CEO. |
November 2015 | Acquired Biopta (Glasgow, Scotland, U.K.) |
October 2014 | REPROCELL USA, the Company’s affiliate in the U.S.A., acquired the business of iPS cell business department of Stemgent (U.S.A.), and changed its name to Stemgent. |
September 2014 | Acquired BioServe (Beltsville, MD, U.S.A.) |
July 2014 | Acquired Reinnervate (County Durham, England, U.K.) |
February 2014 | Consignment and entrustment agreement with Japan Blood Products Organization for the clinical laboratory measurement work. |
February 2014 | Establishment of RC Partners, Inc., which is the Company’s affiliate to invest in a general partner of the venture capital fund called “Cell Innovation Partners, L.P.” that focuses on the creation of next-generation pharmaceutical and medical businesses. |
November 2013 | Launch of custom-made disease model cells in collaboration with Takara Bio, Inc. (Cell products) |
October 2013 | Shin-Yokohama District (REPROCELL, Inc) was chosen as the Life Innovation Comprehensive Special Zones for International Competitiveness Development. |
June 2013 | Listed on the Osaka Securities Exchange JASDAQ Growth Market. |
December 2012 | Establishment of the sales office of REPROCELL USA Inc. in Boston. |
October 2012 | Professor Shinya Yamanaka of Kyoto University received the Nobel Prize in Physiology or Medicine. |
August 2012 | Establishment of agreement for sales collaboration concerning human iPS cells model for Alzheimer’s disease with PerkinElmer Japan Co., Ltd. |
June 2012 | Launch of human iPSC-derived neuron model cells for Alzheimer’s disease. |
May 2012 | Human iPSC-derived hepatocytes (ReproHepato) launch |
October 2011 | A new version of human iPSC-derived cardiomyocytes (ReproCardio2, frozen) launch |
April 2011 | A new feeder-free culture medium ReproFF2 launched |
April 2011 | REPROCELL USA, Ltd. established |
October 2010 | Human iPSC-derived DA neuron (ReproNeuro DA) launch |
January 2010 | The headquarters and laboratory have moved to Yokohama |
April 2009 | Human iPSC-derived cardiomyocytes (ReproCardio) and the assay service using it (QTempo) launch |
August 2008 | Cardiotoxicity testing (QTempo) using monkey ES cell-derived cardiomyocytes launch |
July 2005 | National granted project with Kyoto University and pharmaceutical companies “Drug screening and toxicity technology using human ES cells” (2005 to 2010) |
June 2005 | Laboratory installed in Tokyo |
April 2005 | Launch of research reagent business: Primate ES cell medium |
August 2004 | Start commercializing Nanog antibodies (human, mouse) |
June 2003 | Joint research agreement with Kyoto University |
May 2003 | Joint research agreement with Tokyo University |
February 2003 | REPROCELL Inc. Established |
News and Information
Investor Relations
Products and Services
© 2021 REPROCELL Inc. All rights reserved.